A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

August 12, 2021

Study Completion Date

August 12, 2021

Conditions
Nonalcoholic Fatty Liver Disease
Interventions
DRUG

BMS-963272

Specified dose on specified days

OTHER

Placebo matching BMS-963272

Specified dose on specified days

Trial Locations (19)

32127

Local Institution, Port Orange

33014

Local Institution, Miami

33016

Floridian Clinical Research, Miami Lakes

33147

Advanced Pharma - Miami, Miami

33434

Local Institution, Boca Raton

33472

RecioMed Clinical Research Network, Boynton Beach

35055

Cullman Clinical Trials, Cullman

37421

Local Institution, Chattanooga

38138

Local Institution, Germantown

39532

Local Institution, Biloxi

64131

Local Institution, Kansas City

71220

Local Institution, Bastrop

78215

Local Institution, San Antonio

78229

Local Institution, San Antonio

78504

Local Institution, McAllen

78539

Local Institution, Edinburg

78757

Pinnacle Clinical Research - Austin, Austin

85224

Local Institution, Chandler

85712

Arizona Liver Health - Tucson, Tucson

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04766476 - A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter